Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39596286

Authors

Nicola Mlynarz

Milosz Miedziaszczyk

Barbara Wieckowska

Edyta Szalek

Katarzyna Lacka

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome (MS) comprises several symptoms or disorders that significantly increase the risk of developing atherosclerosis and type 2 diabetes. This study aims to determine the direct impact of testosterone therapy on the components of MS; although excluding type 2 diabetes cases. The authors conducted a systematic literature search of PubMed, Scopus, and Cochrane databases without date limits, using keywords such as "testosterone therapy", "metabolic syndrome" and "men". The studies included in our review focused on the effects of testosterone replacement therapy (TRT) in male patients with MS, yet rejecting individuals where type 2 diabetes constituted the only diagnosis. A meta-analysis was performed using PQStat v1.8.6 software. The overall effect size (mean difference) was calculated using a random effects model. Our meta-analysis indicates that testosterone therapy leads to improvement in the components of MS. Significant reductions were observed in waist circumference (WC) (95% CI: -0.709 to 0.094; = 0.011), as well as in triglycerides (TG) (95% CI: -0.474 to 0.120; = 0.039). These findings support the potential therapeutic benefits of testosterone treatment in managing MS. However, further research is vital to explore the long-term effects and the safety of this therapy in patients with metabolic syndrome.

References

Reaven G . Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 2005; 1(1):9-14. DOI: 10.1016/j.cmet.2004.12.001. View

Taniguchi H, Shimada S, Kinoshita H . Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile Function: A Systematic Review and Meta-Analysis. Urol Int. 2021; 106(6):539-552. DOI: 10.1159/000520135. View

Camacho E, Huhtaniemi I, ONeill T, Finn J, Pye S, Lee D . Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013; 168(3):445-55. DOI: 10.1530/EJE-12-0890. View

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

Haider A, Yassin A, Haider K, Doros G, Saad F, Rosano G . Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016; 12:251-61. PMC: 4913536. DOI: 10.2147/VHRM.S108947. View

Jarecki P, Herman W, Pawliczak E, Lacka K . Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?. Diabetes Metab Syndr Obes. 2019; 12:2181-2191. PMC: 6814954. DOI: 10.2147/DMSO.S218545. View

Singh R, Artaza J, Taylor W, Braga M, Yuan X, Gonzalez-Cadavid N . Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2005; 147(1):141-54. PMC: 4417624. DOI: 10.1210/en.2004-1649. View

Traish A . Major cardiovascular disease risk in men with testosterone deficiency (hypogonadism): appraisal of short, medium and long-term testosterone therapy - a narrative review. Sex Med Rev. 2023; 11(4):384-394. DOI: 10.1093/sxmrev/qead031. View

Barone B, Napolitano L, Abate M, Cirillo L, Reccia P, Passaro F . The Role of Testosterone in the Elderly: What Do We Know?. Int J Mol Sci. 2022; 23(7). PMC: 8998588. DOI: 10.3390/ijms23073535. View

10.

Kalinchenko S, Tishova Y, Mskhalaya G, Gooren L, Giltay E, Saad F . Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010; 73(5):602-12. DOI: 10.1111/j.1365-2265.2010.03845.x. View

11.

Puddu P, Lanti M, Menotti A, Mancini M, Zanchetti A, Cirillo M . Red blood cell count in short-term prediction of cardiovascular disease incidence in the Gubbio population study. Acta Cardiol. 2002; 57(3):177-85. DOI: 10.2143/AC.57.3.2005387. View

12.

Li S, Zhao Y, Yang Y, Wang X, Nie M, Wu X . Metabolic Effects of Testosterone Replacement Therapy in Patients with Type 2 Diabetes Mellitus or Metabolic Syndrome: A Meta-Analysis. Int J Endocrinol. 2020; 2020:4732021. PMC: 7545471. DOI: 10.1155/2020/4732021. View

13.

Luther P, Spillers N, Talbot N, Sinnathamby E, Ellison D, Kelkar R . Testosterone replacement therapy: clinical considerations. Expert Opin Pharmacother. 2024; 25(1):25-35. DOI: 10.1080/14656566.2024.2306832. View

14.

Ly L, Liu P, Handelsman D . Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Hum Reprod. 2005; 20(6):1733-40. DOI: 10.1093/humrep/deh834. View

15.

Chait A . Hypertriglyceridemia. Endocrinol Metab Clin North Am. 2022; 51(3):539-555. DOI: 10.1016/j.ecl.2022.02.010. View

16.

Sarafidis P, Nilsson P . The metabolic syndrome: a glance at its history. J Hypertens. 2006; 24(4):621-6. DOI: 10.1097/01.hjh.0000217840.26971.b6. View

17.

Jarecki P, Herman W, Losy J, Lacka K . The Comparison of Predictive Value Among Chemerin, IL-18 and Hormonal Parameters in Assessing the Risk of Metabolic Syndrome in Men. Am J Mens Health. 2021; 15(4):15579883211034984. PMC: 8326632. DOI: 10.1177/15579883211034984. View

18.

Kelly D, Jones T . Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013; 217(3):R25-45. DOI: 10.1530/JOE-12-0455. View

19.

Pastuszak A, Gomez L, Scovell J, Khera M, Lamb D, Lipshultz L . Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sex Med. 2015; 3(3):165-73. PMC: 4599554. DOI: 10.1002/sm2.76. View

20.

Ambroselli D, Masciulli F, Romano E, Catanzaro G, Besharat Z, Massari M . New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. Nutrients. 2023; 15(3). PMC: 9921449. DOI: 10.3390/nu15030640. View